What medications are recommended for treating heart failure in patients with renal impairment?

Heart Failure Medications Safe for Patients with Renal Impairment

Beta-blockers, SGLT2 inhibitors (dapagliflozin, empagliflozin), and ACE inhibitors/ARBs (with dose adjustments) are the cornerstone medications for treating heart failure in patients with kidney disease, as they improve survival and reduce hospitalizations across all stages of chronic kidney disease. 1, 2

First-Line Medications That Are Safe and Effective

Beta-Blockers

• Beta-blockers are the safest heart failure medication class for patients with renal impairment and should be used in all CKD stages, including dialysis patients. 1, 2
• They improve outcomes in heart failure with reduced ejection fraction (HFrEF) regardless of kidney function level. 1
• Atenolol requires dose reduction: use half dose (50 mg/day) when creatinine clearance is 15-35 mL/min, and quarter dose (25 mg/day) when creatinine clearance is <15 mL/min. 3
• Other beta-blockers (carvedilol, metoprolol succinate, bisoprolol) do not require renal dose adjustment and are preferred. 1

SGLT2 Inhibitors (Sodium-Glucose Cotransporter-2 Inhibitors)

• Dapagliflozin and empagliflozin are highly effective in heart failure patients with moderate-to-severe CKD and provide both cardiac and kidney protection. 4, 5, 6
• Dapagliflozin reduces the composite endpoint of ≥50% decline in eGFR, end-stage kidney disease, or cardiovascular/renal death by 39% in CKD patients (HR: 0.61). 4
• Dapagliflozin can be used safely in patients with eGFR as low as 20 mL/min/1.73 m² without dose adjustment. 4, 5
• Empagliflozin reduces cardiovascular death or heart failure hospitalization equally in patients with and without CKD (HR: 0.78 in CKD patients). 6
• Both medications slow the progressive decline in kidney function and reduce all-cause mortality. 4, 5, 6

ACE Inhibitors and ARBs

• ACE inhibitors and ARBs improve survival in patients with mild-to-moderate CKD (eGFR 30-60 mL/min/1.73 m²) but require careful monitoring and dose adjustments. 1, 2
• Ramipril requires dose adjustment when creatinine clearance is <30 mL/min: start with 1.25 mg daily and do not exceed 5 mg/day. 3
• Monitor renal function 1-2 weeks after initiation or dose increase; accept up to 25% decrease in eGFR or 30% increase in creatinine as tolerable. 3
• Discontinue if creatinine increases >30% from baseline or potassium exceeds 6.0 mmol/L. 3
• Evidence for ACE inhibitors/ARBs is limited in severe CKD (eGFR <30 mL/min) as most trials excluded these patients. 1, 2

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)

• ARNIs (sacubitril/valsartan) have been successfully used in patients with eGFR as low as 20 mL/min/1.73 m². 1
• They provide similar benefits to ACE inhibitors/ARBs but with additional neprilysin inhibition. 1
• Follow the same monitoring protocols as ACE inhibitors/ARBs. 3

Medications Requiring Special Consideration

Mineralocorticoid Receptor Antagonists (Spironolactone)

• Spironolactone improves outcomes in advanced heart failure but carries high risk of hyperkalemia in CKD patients, especially when combined with ACE inhibitors or ARBs. 3, 2
• Monitor potassium at 1 week, then at 1,2,3,6 months, and every 6 months thereafter if stable. 3
• Reduce dose by half if potassium reaches 5.5-5.9 mmol/L; discontinue if potassium reaches ≥6.0 mmol/L. 3
• Use is limited in severe renal insufficiency due to hyperkalemia risk. 2

Loop Diuretics

• Loop diuretics (furosemide, bumetanide, torasemide) are the preferred diuretics in patients with CKD and remain effective even in severe renal impairment. 3, 7
• Higher doses are often required as kidney function declines. 3
• Monitor for hypovolemia, electrolyte disturbances (hypokalemia, hypomagnesemia), and worsening renal function. 3
• Consider switching from furosemide to bumetanide or torasemide for better bioavailability if diuretic resistance develops. 3

Medications to AVOID in Renal Impairment

Thiazide Diuretics (Hydrochlorothiazide)

• Hydrochlorothiazide becomes completely ineffective when creatinine clearance falls below 30 mL/min and should be replaced with loop diuretics. 7
• Even in moderate CKD (eGFR 30-60 mL/min), thiazides have reduced efficacy. 7
• Avoid in severe renal impairment (GFR <30 mL/min). 7

Medications Requiring Extreme Caution

• NSAIDs should be avoided as they worsen renal function, cause fluid retention, and increase risk of acute kidney injury when combined with ACE inhibitors/ARBs. 3, 7
• Glyburide has the highest risk of drug-induced hypoglycemia in older adults with CKD and should be avoided. 3
• Nitrofurantoin requires dose adjustment in CKD. 3

Monitoring Algorithm for Heart Failure Medications in CKD

Baseline Assessment

• Check eGFR, serum creatinine, potassium, and magnesium before initiating any heart failure medication. 3
• Assess volume status and optimize fluid balance. 3

During Initiation and Titration

• Recheck renal function and electrolytes 1-2 weeks after starting or increasing doses of ACE inhibitors, ARBs, ARNIs, or mineralocorticoid receptor antagonists. 3
• For aldosterone antagonists specifically, monitor at 1 week, then 1,2,3, and 6 months. 3
• Continue dose titration if creatinine increase is <30% and potassium remains <6.0 mmol/L. 3

Stable Maintenance Phase

• Monitor renal function and electrolytes every 3 months for patients on ACE inhibitors/ARBs. 3
• Monitor every 6 months for patients on aldosterone antagonists if stable. 3
• Monitor every 6 months for stable heart failure patients not on renin-angiotensin-aldosterone system inhibitors. 3

When to Adjust or Stop Medications

• Reduce or discontinue ACE inhibitors/ARBs if creatinine increases >30% from baseline or potassium exceeds 6.0 mmol/L. 3
• Temporarily withhold diuretics and RAAS inhibitors during acute illness, dehydration, or procedures requiring contrast. 3, 7
• Reduce aldosterone antagonist dose by half if potassium is 5.5-5.9 mmol/L; stop if ≥6.0 mmol/L. 3

Critical Pitfalls to Avoid

• Do not assume worsening creatinine always means medication harm—small increases in creatinine with ACE inhibitors/ARBs (up to 30%) are acceptable and not associated with worse outcomes. 8
• Do not continue hydrochlorothiazide in patients whose kidney function deteriorates to eGFR <30 mL/min during treatment—it becomes ineffective. 7
• Do not combine spironolactone with ACE inhibitors/ARBs without intensive potassium monitoring—this combination dramatically increases hyperkalemia risk. 3, 2
• Do not overlook drug interactions with NSAIDs, which substantially increase nephrotoxicity risk when combined with diuretics and RAAS inhibitors. 3, 7